Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[111In]-FPI-2107 in Chinese Adult Participants With EGFR Mutation-positive NSCLC
NCT07500987Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [111In]-FPI-2107 in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability at 21 days and Dosimetry parameter. Started Feb 2026; status: terminated.
02
Drugs
[111In]-FPI-2107
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07500987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500987.